With all eyes on 31 January 2023 as the expected start of US biosimilar competition to AbbVie’s Humira (adalimumab), there is still the potential for surprises that could upend expectations around this landmark loss of exclusivity for the top-selling biologic brand.
Although Amgen is currently expected to enter the market first – through a settlement with AbbVie connected to its Amjevita (adalimumab-atto) biosimilar – Alvotech’s AVT02 higher-strength 100mg/ml biosimilar represents something of a wild card, with the biosimilars firm still